Based on the WuXi AppTec Co. Ltd stock forecast from 0 analysts, the average analyst target price for WuXi AppTec Co. Ltd is not available over the next 12 months. WuXi AppTec Co. Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of WuXi AppTec Co. Ltd is Slightly Bullish , which is based on 9 positive signals and 7 negative signals. At the last closing, WuXi AppTec Co. Ltd’s stock price was USD 7.12. WuXi AppTec Co. Ltd’s stock price has changed by -4.94% over the past week, +88.36% over the past month and -28.30% over the last year.
No recent analyst target price found for WuXi AppTec Co. Ltd
No recent average analyst rating found for WuXi AppTec Co. Ltd
Company Overview WuXi AppTec Co. Ltd
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs and advanced therapies in the People's Republic of China, the United States, Europe, and internationally. The company operates in six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; and drug discovery services to pharmaceutical and biotech customers. In addition, the company offers consulting services for combinatorial chemistry and pharmaceuticals; and develops computer software and databases. Further, it is involved in pharmaceutical research and development; pharmacology, toxicology, and safety evaluation research services; and new drug clinical development and on-site management services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China. Read Less
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs and advanced therapies in the People's Republic of China, the United States, Europe, and internationally. The...Read More
Frequently Asked Questions About WuXi AppTec Co. Ltd (WUXIF) Stock
Stock Target Advisor's fundamental analysis for WuXi AppTec Co. Ltd's stock is Slightly Bullish .
WUXIF stock's dividend yield is 1.86%.
Our analysis grades WUXIF stock's dividend yield at F. This means that WUXIF stock's dividend yield is above 56% of the stocks in the Diagnostics & Research sector in the OTC exchange.
Based on this WUXIF may be a average dividend stock for its sector.
Unfortunately we do not have enough data on WUXIF's stock to indicate what its average analyst target is.
WUXIF stock's Price/Earning ratio is 19.71.
Our analysis grades WUXIF stock's Price / Earning ratio at F. This means that WUXIF stock's Price/Earning ratio is above 50% of the stocks in the Diagnostics & Research sector in the OTC exchange.
Based on this WUXIF may be fairly valued for its sector
The last closing price of WUXIF's stock was USD 7.12.
The most recent market capitalization for WUXIF is USD 22.23B.
Unfortunately we do not have enough analyst data on WUXIF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains WuXi AppTec Co. Ltd's stock.
As per our most recent records WuXi AppTec Co. Ltd has 41,116 Employees.
WuXi AppTec Co. Ltd's registered address is 288 Fute Zhong Road, Shanghai, China, 200131.
You can get more information about it from WuXi AppTec Co. Ltd's website at https://www.wuxiapptec.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About WuXi AppTec Co. Ltd (WUXIF) Stock
Stock Target Advisor's fundamental analysis for WuXi AppTec Co. Ltd's stock is Slightly Bullish .
WUXIF stock's dividend yield is 1.86%.
Our analysis grades WUXIF stock's dividend yield at F. This means that WUXIF stock's dividend yield is above 56% of the stocks in the Diagnostics & Research sector in the OTC exchange.
Based on this WUXIF may be a average dividend stock for its sector.
Unfortunately we do not have enough data on WUXIF's stock to indicate what its average analyst target is.
WUXIF stock's Price/Earning ratio is 19.71.
Our analysis grades WUXIF stock's Price / Earning ratio at F. This means that WUXIF stock's Price/Earning ratio is above 50% of the stocks in the Diagnostics & Research sector in the OTC exchange.
Based on this WUXIF may be fairly valued for its sector
The last closing price of WUXIF's stock was USD 7.12.
The most recent market capitalization for WUXIF is USD 22.23B.
Unfortunately we do not have enough analyst data on WUXIF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains WuXi AppTec Co. Ltd's stock.
As per our most recent records WuXi AppTec Co. Ltd has 41,116 Employees.
WuXi AppTec Co. Ltd's registered address is 288 Fute Zhong Road, Shanghai, China, 200131.
You can get more information about it from WuXi AppTec Co. Ltd's website at https://www.wuxiapptec.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for WUXIF !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
